Gimv Sells Stake in ImCheck Therapeutics to Ipsen

Gimv Life Sciences has announced the sale of its stake in ImCheck Therapeutics to Ipsen. This transaction marks a pivotal moment for both companies. Gimv's strategic investment in life sciences is underscored by ImCheck’s advances in immunotherapy, particularly for acute myeloid leukemia (AML). The lead program, ICT01, has shown promising results, nearly doubling treatment response rates in clinical trials.

The agreement includes an upfront payment of 350 million euros to Gimv and potential milestone-related payments that could increase the total deal value to nearly 1 billion euros. For Gimv, this sale brings a 2.6x return on their investment, with further potential gains if regulatory milestones are met.

Completion of the transaction is anticipated by the end of Q1 2026, pending necessary regulatory approvals. Ipsen aims to leverage its expertise to further develop and commercialize ICT01, positioning it as a new standard of care for high-risk AML patients.